Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis

Jiuyang Xu1,*, Chaolin Huang2,* , Guohui Fan3,4,5,*, Zhibo Liu3,4,*, Lianhan Shang3,4,6, Fei Zhou3,4, Yeming Wang3,4,7, Jiapei Yu1, Luning Yang1, Ke Xie3,7, Zhisheng Huang3,8, Lixue Huang3,7, Xiaoying Gu3,4,5, Hui Li3,4, Yi Zhang3,4, Yimin Wang3,4, Frederick G. Hayden9, Peter W. Horby10, Bin Cao (✉)3,4,7,11, Chen Wang (✉)3,4,11,12

1Department of Basic Medical Sciences, Tsinghua University School of Medicine, Beijing 100084, China; 2Department of Infectious Diseases, Jinyintan Hospital, Wuhan 430030, China; 3Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China; 4Institute of Respiratory Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China; 5Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing 100029, China; 6Beijing University of Chinese Medicine, Beijing 100029, China; 7Department of Respiratory Medicine, Capital Medical University, Beijing 100029, China; 8Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China; 9Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA 22904, USA; 10Centre for Tropical Medicine and Global Health, University of Oxford, Oxford OX1 2JD, UK; 11Tsinghua University–Peking University Joint Center for Life Sciences, Beijing 100084, China; 12Chinese Academy of Engineering, Beijing 100088, China

© Higher Education Press 2020

Abstract  The possible effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on COVID-19 disease severity have generated considerable debate. We performed a single-center, retrospective analysis of hospitalized adult COVID-19 patients in Wuhan, China, who had definite clinical outcome (dead or discharged) by February 15, 2020. Patients on anti-hypertensive treatment with or without ACEI/ARB were compared on their clinical characteristics and outcomes. The medical records from 702 patients were screened. Among the 101 patients with a history of hypertension and taking at least one anti-hypertensive medication, 40 patients were receiving ACEI/ARB as part of their regimen, and 61 patients were on anti-hypertensive medication other than ACEI/ARB. We observed no statistically significant differences in percentages of in-hospital mortality (28% vs. 34%, P = 0.46), ICU admission (20% vs. 28%, P = 0.37) or invasive mechanical ventilation (18% vs. 26%, P = 0.31) between patients with or without ACEI/ARB treatment. Further multivariable adjustment of age and gender did not provide evidence for a significant association between ACEI/ARB treatment and severe COVID-19 outcomes. Our findings confirm the lack of an association between chronic receipt of renin-angiotensin system antagonists and severe outcomes of COVID-19. Patients should continue previous anti-hypertensive therapy until further evidence is available.

Keywords  COVID-19; SARS-CoV-2; hypertension; angiotensin-converting enzyme inhibitor; angiotensin II receptor blocker

Introduction

The coronavirus disease 2019 (COVID-19) outbreak has spread across the world with more than 5.1 million confirmed cases [1]. Early reports on clinical characteristics have identified hypertension as the most common comorbidity reported in COVID-19 patients [2–5]. Zhou et al. documented pre-existing hypertension as a risk factor for in-hospital death of COVID-19 [6]. This observation is of great interest since the renin-angiotensin system (RAS) is an important component in regulating blood pressure, and the transmembrane angiotensin-converting enzyme 2...
(ACE2), which catalyzes the cleavage of angiotensin II (a vasoconstrictor) into vasodilatory peptides, is also the cellular entry receptor for SARS-CoV-2.

Given the common use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in patients with cardiovascular diseases [7], there has been wide discussion whether administration of ACEI/ARB might modulate COVID-19 disease severity. Concerns have been raised whether hypertensive patients should stop taking ACEI/ARB and switch to other anti-hypertensive drugs in the context of COVID-19 pandemic [8,9]. There have also been counter-arguments in favor of the use of ACEI/ARB in COVID-19 patients, based on previous studies showing that ACEI/ARB are associated with improvements in pneumonia-related outcomes [10,11], as well as a protective role of ARBs in SARS-CoV and influenza infected animals [12,13].

The renin-angiotensin system (RAS) plays a central role in regulating blood pressure and maintaining hemodynamic homeostasis. In hypovolemic conditions, angiotensinogen is serially cleaved by renin and angiotensin-converting enzyme (ACE) into angiotensin I (Ang I) and angiotensin II (Ang II), respectively. Ang II then acts on the cellular receptor angiotensin II receptor I (AT1) to constrict the blood vessels and increases blood pressure (Fig. 1). To counteract this vaso-constrictive effect of RAS,

---

**Fig. 1** Physiology of ACE/AngII/AT1 and ACE2/Ang1–7/Mas axes. (A) Schematic structures of angiotensin and its derivatives. The three-letter codes were used to represent amino acid residues. (B) Physiology of angiotensin processing and blood regulation. In hypovolemic conditions, renin, secreted by cells in macula densa in the kidney, cleaves angiotensinogen into a decapeptide angiotensin I (Ang I). The angiotensin-converting enzyme (ACE) further cleaves the peptide into an octapeptide angiotensin II (Ang II), which acts on the cellular receptor angiotensin II receptor I (AT1) to constrict the blood vessels and increases blood pressure (“yang”). ACE2 is a monocarboxypeptidase transforming the Ang II into angiotensin-(1–7) (Ang1–7), which binds to the G protein-coupled receptor Mas to dilate the blood vessels and counter-balance ACE/Ang II in blood pressure regulation (“yin”). Figure was generated with BioRender.
the human body has developed another system in an exquisite “yin-yang” balance. The ACE2 is a homolog of ACE [14,15] that metabolizes Ang II into angiotensin-(1–7) (Ang1–7), which dilates the blood vessels and counter-balance ACE/Ang II in blood pressure regulation [16] (Fig. 1). Of note, in a rat model of lipopolysaccharide-induced acute respiratory distress syndrome (ARDS), reduced pulmonary levels of Ang1–7 contribute to disease pathogenesis, and administration of this peptide or the ARB losartan reduces the development of ARDS [17]. The non-angiotensinase function of ACE2 was recognized when it was identified to be cellular receptor for severe acute respiratory syndrome coronavirus (SARS-CoV) [18], as well as more recently for SARS-CoV-2 [19–21]. ACE2 expression has been documented in various human organs, including oral and nasal mucosa, lung, intestine, kidney, heart, arterial/venous endothelium and others [22–25].

High-quality clinical evidence for ACEI/ARB usage in COVID-19 patients is insufficient to draw definitive conclusions whether chronic ACEI/ARB should be continued or stopped [26]. Several recent retrospective, hospital-based studies have reported no adverse or marginal protective effect of ACEI/ARB on the clinical outcomes of COVID-19 patients [27–32]. To contribute to this discussion, we have performed a secondary analysis on a previously-reported single-center retrospective cohort of COVID-19 patients in Wuhan, China [6].

**Materials and methods**

**Study design and data collection**

We previously collected data from 702 hospitalized adult COVID-19 patients admitted to Jinyintan Hospital (Wuhan, China), who had definite outcome (dead or discharged) between December 29, 2019 and February 15, 2020 [6]. Data were extracted from medical records into an electronic data collection form by two independent researchers. Their electronic medical records were screened for medical history of hypertension in past medical history or admitting diagnosis and for oral anti-hypertensive treatment before and during hospitalization. The anti-hypertensive treatments we included in the analysis were ACEI, ARB, β-blockers, calcium channel blockers (CCBs), diuretics, and others (α-blockers and traditional Chinese medicine). Patients with definitive long-term anti-hypertensive treatments, as either recorded in the medical history or in the prescribed medication chart as standing order during hospitalization, were included in the final analysis. The comorbidities were either self-reported by the patients or evaluated by attending physicians and recorded in admitting diagnosis.

The study was approved by the Research Ethics Commission of Jinyintan Hospital (KY-2020-01.01) and the informed consent was waived by the Research Ethics Commission.

**Definitions**

Fever was defined as axillary temperature of at least 37.3 °C. Sepsis and septic shock were evaluated based on Sepsis-3 International Consensus [33]. ARDS was diagnosed according to the Berlin Definition [34]. Acute kidney injury was defined according to the KDIGO clinical practice guidelines [35]. Diagnosis of acute cardiac injury was made if serum levels of high-sensitive cardiac troponin I was above the 99th percentile upper reference limit [36]. Secondary infection, hypoproteinemia, and coagulopathy were defined as previously [6].

**Statistical analysis**

Continuous variables were expressed as median (interquartile range (IQR)) and categorical variables as number (proportion). Two-group comparisons (ACEI/ARB vs. non-ACEI/ARB) were conducted with Mann–Whitney U test or χ²/Fisher exact test where appropriate. The risk of death, ICU admission, invasive mechanical ventilation and corresponding odds ratio both with and without adjustment for age and gender were calculated by Logistic model, comparing patients in ACEI/ARB group with those in non-ACEI/ARB group. Four previously-reported risk factors for death (age, history of diabetes, qSOFA score, and D-dimer) were included in univariable and multivariable analysis with Logistic model. A 2-sided α less than 0.05 was considered statistically significant. Statistical analyses were conducted using SAS software (version 9.4, SAS Institute) and SPSS software (version 25, IBM).

**Results**

**Patients and clinical characteristics**

A total of 702 adult laboratory-confirmed COVID-19 patients admitted to Jinyintan Hospital, who had definite clinical outcome by February 15, 2020, were screened in this study, of whom 188 patients had a medical history of hypertension. Among them, 101 patients had anti-hypertensive treatment medications recorded in their medical records and were included in the final analysis. The schematic of patient selection is shown in Fig. 2. Patients who took ACEI or ARB as part of their anti-hypertensive therapy were included in the ACEI/ARB cohort (n = 40), and those without were categorized in the non-ACEI/ARB cohort (n = 61).

Patients in ACEI/ARB group and non-ACEI/ARB group were comparable in age (median, 66.5 vs. 65.0 years, P = 0.80) and gender distribution (male, 48% vs.
56%, \( P = 0.42 \)), as shown in Table 1. They were also in similar phase of the disease with median time from symptom onset to admission being 12.5 days (IQR 8.5–16.0 days) and 13.0 days (IQR 8.5–15.5 days), respectively. In addition to hypertension, patients in two groups also shared similar proportions of comorbidities and smoking history.

The vital signs and laboratory test results on admission were generally similar between the two groups (Table 1). Comparable proportions of patients in two groups had lymphocyte count less than 0.8 \( \times 10^9 \) \( /L \) (55% vs. 48%, \( P = 0.51 \)), increased serum cardiac troponin I (18% vs. 19%, \( P = 0.88 \)), and increased serum D-dimer levels (59% vs. 58%, \( P = 0.95 \)). The percentages of heart failure, defined as brain natriuretic peptide (BNP) value \( \geq 100 \) pg/mL on admission, were also similar among the two groups (28% vs. 27%, \( P = 0.93 \)). Values of the inflammatory markers, including serum ferritin, procalcitonin, and interleukin-6 were not different between the two groups, nor were chest imaging features distinguishable. The sequential organ failure assessment (SOFA) scores in ACEI/ARB group (median 2.0, IQR 1.0–4.0) were numerically smaller than those in non-ACEI/ARB group (median 4.0, IQR 2.0–4.5), although the difference is not statistically significant (\( P = 0.29 \)).

**Anti-hypertensive treatment**

Among the 101 patients recorded with anti-hypertensive medication, 40 cases had therapies based on ACEI/ARB, either as mono-therapy or combined with \( \beta \)-blockers, CCB, thiazide diuretics or spironolactone (Tables 2 and 3). No usage of sacubitril-valsartan was reported in this cohort. The non-ACEI/ARB therapy was mostly based on calcium channel blockers (Tables 2 and 3). The usage of other anti-hypertensive medications (\( \alpha \)-blocker, \( \beta \)-blocker, and diuretics) was comparable between the two groups (Table 2). Similar percentages of patients were under optimal blood pressure control based on the vital signs taken on admission (Table 1). Chronic treatment on RAS antagonists was not associated with statistically significant changes in serum electrolyte (sodium and potassium) or serum creatinine levels (Table 1).

**Association between ACEI/ARB usage with severe clinical outcome of COVID-19**

Compared with the hypertensive patients who were not given ACEI/ARB, we observed no significant differences in percentages of in-hospital mortality (28% vs. 34%, \( P = 0.46 \)), ICU admission (20% vs. 28%, \( P = 0.37 \)), or mechanical ventilation (18% vs. 26%, \( P = 0.31 \)) in those receiving a regimen that included an ACEI or ARB. Of note, the percentages with these major outcomes were uniformly smaller in ACEI/ARB group. Similarly, numerically fewer patients in ACEI/ARB group developed respiratory failure (43% vs. 59%, \( P = 0.10 \)), sepsis (48% vs. 59%, \( P = 0.26 \)) or ARDS (28% vs. 36%, \( P = 0.37 \))
Table 1  Demographic, clinical, laboratory, and radiologic findings on admission

| Characteristics                              | Total   | ACEI/ARB | Non-ACEI/ARB | P value |
|----------------------------------------------|---------|----------|--------------|---------|
| **n = 101**                                  |         | n = 40   | n = 61       |         |
| **Age (year)**                               | 65.0 (58.0, 73.0) | 66.5 (58.0, 72.0) | 65.0 (58.0, 74.0) | 0.8024 |
| **Gender, male, n (%)**                      | 53 (52) | 19 (48)  | 34 (56)      | 0.4175 |
| **Smoking, n (%)**                           | 4 (4)   | 3 (8)    | 1 (2)        | 0.3394 |
| **Time from illness onset to admission (day)**| 13.0 (8.5, 16.0) | 12.5 (8.5, 16.0) | 13.0 (8.5, 15.5) | 0.7805 |
| **Comorbidity**                              |         |          |              |         |
| Hypertension, n (%)                          | 101 (100) | 40 (100) | 61 (100) | NA     |
| Diabetes, n (%)                              | 19 (19) | 8 (20)   | 11 (18)     | 0.8046 |
| Heart failure, n (%)                         | 1 (1)   | 0 (0)    | 1 (2)       | 1.0000 |
| Coronary heart disease, n (%)                | 12 (12)| 5 (13)   | 7 (11)      | 1.0000 |
| COPD, n (%)                                  | 2 (2)   | 1 (3)    | 1 (2)       | 1.0000 |
| Carcinoma, n (%)                             | 5 (5)   | 2 (5)    | 3 (5)       | 1.0000 |
| Chronic kidney disease, n (%)                | 2 (2)   | 0 (0)    | 2 (3)       | 0.5168 |
| **Vital signs**                              |         |          |              |         |
| Respiratory rate>24 /min, n (%)              | 19 (19) | 6 (15)   | 13 (21)     | 0.4273 |
| Systolic BP (mmHg)                           | 135 (122, 152) | 138 (131, 152) | 134 (123, 147) | 0.6617 |
| ≥140, n (%)                                  | 39 (39) | 17 (43)  | 22 (36)     | 0.5160 |
| Diastolic BP (mmHg)                          | 81 (75, 88) | 79 (74, 90) | 82 (76, 87) | 0.4222 |
| ≥90 mmHg, n (%)                              | 22 (22) | 11 (28)  | 11 (18)     | 0.2596 |
| **Symptoms**                                 |         |          |              |         |
| Fever, n (%)                                 | 88 (87) | 31 (78)  | 57 (93)     | 0.0193 |
| Cough, n (%)                                 | 80 (79) | 30 (75)  | 50 (82)     | 0.3988 |
| Sputum, n (%)                                | 30 (30) | 11 (28)  | 19 (31)     | 0.6948 |
| Myalgia, n (%)                               | 9 (9)   | 2 (5)    | 7 (11)      | 0.4472 |
| Headache, n (%)                              | 9 (9)   | 5 (13)   | 4 (7)       | 0.5040 |
| Fatigue, n (%)                               | 39 (39) | 15 (38)  | 24 (39)     | 0.8523 |
| Diarrhea, n (%)                              | 8 (8)   | 3 (8)    | 5 (8)       | 1.0000 |
| Dyspnea, n (%)                               | 64 (63) | 23 (58)  | 41 (67)     | 0.3217 |
| **Laboratory findings**                      |         |          |              |         |
| Na (mmol/L)                                  | 140.0 (139.0, 142.0) | 141.0 (139.0, 143.0) | 140.0 (139.0, 142.0) | 0.1949 |
| <135                                         | 2 (2)   | 0 (0)    | 2 (3)       | 0.7669 |
| 135–145                                      | 97 (96) | 39 (98)  | 58 (95)     | 0.3988 |
| >145                                         | 2 (2)   | 1 (3)    | 1 (2)       | 0.4472 |
| K (mmol/L)                                   | 4.1 (3.7, 4.5) | 4.1 (3.6, 4.6) | 4.1 (3.7, 4.4) | 0.5923 |
| <3.5                                         | 15 (15) | 4 (10)   | 11 (18)     | 0.5247 |
| 3.5–5.5                                      | 81 (80) | 34 (85)  | 47 (77)     | 0.5247 |
| >5.5                                         | 5 (5)   | 2 (5)    | 3 (5)       | 0.5247 |
| White blood cell count (×10⁹/L)              | 6.0 (4.5, 8.7) | 6.1 (5.0, 9.7) | 5.8 (4.4, 8.2) | 0.5289 |
| 4–10, n (%)                                  | 66/100 (66) | 26 (65)  | 40/60 (67)  | 0.9049 |
| <4, n (%)                                    | 16/100 (16) | 6 (15)   | 10/60 (17)  | 0.8301 |
| >10, n (%)                                   | 18/100 (18) | 8 (20)   | 10/60 (17)  | 0.8301 |
| Lymphocyte count (×10⁹/L)                    | 0.8 (0.6, 1.3) | 0.8 (0.6, 1.3) | 0.8 (0.6, 1.2) | 0.8301 |
| <0.8, n (%)                                  | 51/100 (51) | 22 (55)  | 29/60 (48)  | 0.5135 |
| Hemoglobin (g/L)                             | 121.0 (110.0, 135.5) | 117.5 (108.5, 134.0) | 123.0 (113.0, 136.5) | 0.2601 |
| Platelet count (×10⁹/L)                      | 202.5 (150.0, 261.5) | 189.0 (145.5, 251.5) | 206.0 (162.0, 269.5) | 0.5129 |
| <100, n (%)                                  | 3/100 (3) | 1 (3)    | 2/60 (3)    | 1.0000 |
| Alanine transaminase (U/L)                   | 32.0 (21.0, 54.0) | 32.0 (23.0, 54.0) | 34.0 (20.0, 53.0) | 0.6342 |
| ≤40, n (%)                                   | 62 (61) | 25 (63)  | 37 (61)     | 0.8523 |
| >40, n (%)                                   | 39 (39) | 15 (38)  | 24 (39)     | 1.0000 |
| Creatinine>133 (μmol/L), n (%)               | 6 (6)   | 2 (5)    | 4 (7)       | 1.0000 |
During hospitalization, hospital length of stay and duration of viral shedding for discharged patients were similar between ACEI/ARB and non-ACEI/ARB groups (Table 4). We did not include the non-survivors in the analysis for viral-shedding duration because it has been previously reported that non-survivors had prolonged viral shedding until death [6].

Further multivariable analysis adjusted for age and gender did not provide statistical evidence for association between ACEI/ARB treatment and severe clinical outcome in COVID-19 patients (Table 5). As previously reported in the total population [6], older age, increased D-dimer values (>1µg/mL) and higher qSOFA scores were associated with higher risks of in-hospital mortality in hypertensive COVID-19 patients in the Logistic model (Table 6).

### Discussion

The hypothesis that ACEI or ARB treatment changes COVID-19 disease progression was based in part on potential impact of RAS antagonists on ACE2 expression. Theoretically, does administration of an ACEI or ARB

| Characteristics                              | Total  | ACEI/ARB  | Non-ACEI/ARB  | P value |
|----------------------------------------------|--------|-----------|---------------|---------|
|                                             | n = 101| n = 40    | n = 61        |         |
| Lactate dehydrogenase (U/L)                  | 336.0  | 307.0     | 357.0         | 0.0828  |
| ≤245, n (%)                                  | 28/100 | 13 (33)   | 15/60 (25)    | 0.4132  |
| >245, n (%)                                  | 72/100 | 27 (68)   | 45/60 (75)    |         |
| Creatine kinase (U/L)                        | 15.0   | 38 (95)   | 57/59 (97)    | 1.0000  |
| ≤185, n (%)                                  | 4/99   | 2 (5)     | 2/59 (3)      |         |
| Brain natriuretic peptide (pg/mL)            | 58.6   | 55.7      | 61.2          | 0.6878  |
| >100, n (%)                                  | 17/62  | 7/25 (28) | 10/37 (27)    | 0.9329  |
| Cardiac troponin I (pg/mL)                   | 7.2    | 5.7       | 9.1           | 0.2629  |
| >28, n (%)                                   | 18/99  | 7 (18)    | 11/59 (19)    | 0.8848  |
| Prothrombin time (s)                         | 11.4   | 11.5      | 11.3          | 0.9857  |
| <16, n (%)                                   | 97/99  | 38/39 (97)| 59/60 (98)    | 1.0000  |
| ≥16, n (%)                                   | 2/99   | 1/39 (3)  | 1/60 (2)      |         |
| D-dimer (µg/mL)                              | 1.3    | 1.2       | 1.4           | 0.1759  |
| ≤1, n (%)                                    | 41/99  | 16/39 (41)| 25/60 (42)    | 0.9496  |
| >1, n (%)                                    | 58/99  | 23/39 (59)| 35/60 (58)    |         |
| Serum ferritin (µg/L)                        | 576.9  | 577.1     | 548.8         | 0.9853  |
| <300, n (%)                                  | 17/83  | 8/35 (23) | 9/48 (19)     | 0.6471  |
| >300, n (%)                                  | 66/83  | 27/35 (77)| 39/48 (81)    |         |
| Procalcitonin (ng/mL)                        | 0.1    | 0.1       | 0.1           | 0.2729  |
| <0.1, n (%)                                  | 36/65  | 16/24 (67)| 20/41 (49)    | 0.4237  |
| ≥0.1 to <0.25, n (%)                         | 21/65  | 5/24 (21) | 16/41 (39)    |         |
| ≥0.25 to <0.5, n (%)                         | 2/65   | 1/24 (4)  | 1/41 (2)      |         |
| ≥0.5, n (%)                                  | 6/65   | 2/24 (8)  | 4/41 (10)     |         |
| Interleukin 6 (pg/mL)                        | 7.5    | 7.0       | 8.0           | 0.1429  |
| <10.9, n (%)                                 | 60/65  | 24/66 (36)| 40 (66)       | 0.5696  |
| Imaging features                             |        |           |               |         |
| Consolidation, n (%)                         | 64 (63)| 24 (60)   | 40 (66)       | 0.5696  |
| Ground-glass opacity, n (%)                  | 82 (81)| 32 (80)   | 50 (82)       | 0.8046  |
| Bilateral pulmonary infiltration, n (%)      | 82 (81)| 33 (83)   | 49 (80)       | 0.7847  |
| Disease severity scores                      |        |           |               |         |
| SOFA                                         | 3.5    | 2.0       | 4.0           | 0.2917  |
| CURB-65                                      | 1.0    | 1.0       | 1.0           | 0.6631  |
| 0–1, n (%)                                   | 73 (72)| 28 (70)   | 45 (74)       | 0.7230  |
| 2, n (%)                                     | 20 (20)| 9 (23)    | 11 (18)       |         |
| 3–5, n (%)                                   | 8 (8)  | 3 (8)     | 5 (8)         |         |

Data were presented as median (IQR) or number (proportion). P values for comparison between ACEI/ARB group and non-ACEI/ARB group were calculated by Mann–Whitney U test, Z² test or Fisher’s exact test where appropriate. Abbreviation: COPD, chronic obstructive pulmonary disease; SOFA, sequential organ failure assessment.
have an impact on ACE2 expression or activity? First of all, it has been shown that ACEIs do not affect ACE2 activity [15]. In terms of ACE2 expression, olmesartan, but not other ACEIs, ARBs or calcium channel blockers, has been found to increase urinary ACE2 levels in hypertensive patients [37,38]. Also, ACEI treatment has been reported to increase serum ACE2 activity in diabetic patients [39]. Yet the soluble ACE2 (sACE2) levels do not always reflect the tissue ACE2 expression in lung or other organs. In fact, it is reasonable to hypothesize that sACE2 may even negatively correlate with tissue ACE2 since sACE2 is cleaved from the membrane-bound enzyme before being released into the blood stream. Also, it has to be noted that increase in ACE2 enzymatic activity does not always match the upregulation of ACE2 expression [40,41]. Therefore, change in pulmonary tissue ACE2 after ACEI or ARB treatment has to be directly studied to provide answers for this question, although studies of upper respiratory tract ACE2 expression or ACE2 enzyme activity in bronchoalveolar lavage fluid might provide indirect evidence [42,43]. Hypertensive animal models might be a surrogate before clinical evidence is available. In rat cardiac myocytes, Ang II significantly reduces ACE2 activity and downregulates ACE2 mRNA expression; these effects can be blocked by the ARB losartan, indicating that Ang II regulates ACE2 [24]. Mice deficient for ACE show markedly improved disease in an ARDS model induced by acid aspiration or sepsis, and recombinant ACE2 can protect mice from severe acute lung injury [44]. In mice and rat models, ARB treatment consistently increases ACE2 mRNA and protein levels in heart, kidney, and aorta tissue, although its effect on lung ACE2 expression has not been studied. Also, the effects of ACEI administration on ACE2 expression differs among experiment models and tissues [45]. Animal models of SARS-CoV-2 infection that recapitulate the pathogenesis of severe COVID-19 are needed to better understand the effects of ACE inhibitors and ARBs.

In this single-center retrospective study, we did not observe difference in clinical presentations of patients with or without ACEI/ARB treatment on admission. Nor did we find any important differences in severe clinical outcomes, namely in-hospital death, ICU admission, and mechanical ventilation, in these two groups. However, our preliminary analysis was limited by the retrospective nature of the cohort, its small sample size, and possibly nonrecorded data as the prescription records for drugs not directly relevant to COVID-19 treatment may be incomplete. Only patients with complete anti-hypertensive treatment information were included in the analysis, but this strategy, by excluding about half the hypertensive cases in the original hypertensive cohort, reduced statistical power of this study.

Table 2  Anti-hypertensive treatment therapies

| Treatment | Total n = 101 | ACEI/ARB n = 40 | Non-ACEI/ARB n = 61 | P value |
|-----------|---------------|-----------------|---------------------|---------|
| ACEI      | 8 (8)         | 8 (20)          | 0                   | 0.0011  |
| ARB       | 33 (33)       | 33 (83)         | 0                   | <0.0001 |
| α-blocker | 2 (20)        | 1 (3)           | 1 (2)               | 1.0000  |
| β-blocker | 15 (15)       | 5 (13)          | 10 (16)             | 0.5905  |
| CCB       | 77 (77)       | 19 (48)         | 58 (95)             | <0.0001 |
| Diuretics | 9 (9)         | 6 (15)          | 3 (5)               | 0.1669  |

Data were presented as number (proportion). P values for comparison between ACEI/ARB group and non-ACEI/ARB group were calculated by χ² test or Fisher’s exact test where appropriate. Abbreviation: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker.

Table 3  Anti-hypertensive treatment therapies by combination

| Treatment | Number |
|-----------|--------|
| A*        | 14     |
| B         | 3      |
| C         | 48     |
| A + B     | 3      |
| A + C     | 17     |
| A + D     | 2      |
| B + C     | 7      |
| C + D     | 3      |
| A + C + D | 2      |
| A + B + C + D | 2  |
| Total     | 101    |

*One of 14 patients took valsartan and benazepril. All the other 13 patients were on either ACEI or ARB as mono-therapy. A means angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB); B means β-blocker; C means calcium channel blocker (CCB); D means diuretics. ACEI refers to benazepril in this cohort. ARB medications include valsartan, irbesartan, telmisartan, and candesartan. β-blockers used in this cohort include metoprolol and bisoprolol. CCBs include amlodipine, nifedipine, felodipine, lacidipine, and lercanidipine. Diuretics include hydrochlorothiazide and spironolactone. Other uncommon medications not listed in this table were terazosin (α-blocker) and traditional Chinese medicine with un-specified formula.
statistical difference given two-tailed $\alpha = 0.05$ and $\beta = 0.2$. Although this cohort had enough power to detect the association between older age and increased COVID-19 mortality (Table 6), it is under-powered for the marginal effect of ACEI/ARB on altered clinical outcome if there was association.

Other confounding factors including age should be carefully evaluated before drawing the final conclusion.
from retrospective analysis. It has to be noted that while ACEI/ARB are the most popular anti-hypertensive drug in the US [46], CCBs are more widely used in China [7,47]. This partially explains the high CCB usage in the non-ACEI/ARB group (Tables 2 and 3). After adjustment for the difference of CCB prescription, ACEI/ARB still does not show association with COVID-19 mortality (OR 0.70, 95% CI 0.24–1.99, P = 0.5011). We did not observe association between CCB usage and COVID-19 mortality, either, from this cohort (data not shown). Pre-existing heart failure should also be assessed because RAS antagonists including ACEI, ARB, and aldosterone inhibitors were basic treatment options for chronic heart failure. Proper multivariable adjustment on confounding factors should be implemented in retrospective analysis. We did not adjust for history of heart failure concerning the small sample size and the self-reporting nature of this factor. We did not have information for viral load of patients on admission, because only qualitative RT-PCR test results were available in the medical records. It would be interesting to examine whether chronic ACEI or ARB treatment would affect virus replication in future studies.

Similar to our findings, no association was observed between ACEI/ARB prescription and poor clinical prognosis or severe disease of COVID-19 in several other retrospective cohorts in China [27,28,48,49] or globally [29–32]. Compared with these reports, patients in this cohort were sicker on admission and the in-hospital mortality was higher (32%). This likely related to the study hospital being a referral center with severe cases during early epidemic in Wuhan.

With accumulating information from multiple large cohort studies, it seems clear that prior receipt of ACEI or ARB does not bring additional risks of hospital admission or poor prognosis of COVID-19. The discussion has therefore been gradually shifted to whether chronic treatment of ACEI or ARB before COVID-19 onset is associated with less severe illness. ACEI and ARB have been reported with protective effect in a previous meta-analysis for pneumonia-related mortality in general [10]. In terms of COVID-19, de Abajo et al. found a decreased risk of COVID-19 hospital admission in the subgroup analysis of diabetic patients with RAS inhibitors [31]. Information from other large COVID-19 case series and preferably population-based cohort studies, optimally linked to serologic testing, are necessary to determine whether receipt of ACEI or ARBs are associated with reduced risk of symptomatic SARS-CoV-2 infection and especially of severe COVID-19 illness. Systematic analysis combining data from multiple studies would be helpful in answering this question. There have also been randomized clinical trials in progress studying the efficacy of acute initiation of ACEI for treatment of COVID-19 (e.g., NCT04366050 and NCT04355429).

In conclusion, there has been accumulating evidence for no association between chronic ACEI/ARB treatment and severe outcome of COVID-19. Meanwhile, current studies are pointing toward a putative protective role of prior ACEI or ARB receipt in COVID-19 illness, which awaits further evidence for confirmation. Several professional societies have released statements on continuing current anti-hypertensive treatment during the COVID-19 pandemic [50], considering the risk of destabilizing blood pressure after changing medications. We agree that the best option is to continue previous therapy and wait for further evidence.

Acknowledgements

We acknowledge all health-care workers involved in the diagnosis and treatment of patients in Jinyintan Hospital in Wuhan, China. This work was supported by Major Projects of National Science and Technology on New Drug Creation and Development (Nos. 2020ZX09201001 and 2020ZX09201012); Chinese Academy of Medical Sciences (CAMS) Emergency Project of COVID-19 (No. 2020HY320001).

Compliance with ethics guidelines

Dr. Frederick G. Hayden declares he has served as non-compensated consultant to Cidara, GlaxoSmithKline, Gilead Sciences, resTORbio, Regeneron, SAB Biotherapeutics on coronavirus interventions, outside the submitted work. All other authors declare no competing interests. The study was performed in accordance with the Helsinki Declaration of 1975, and was approved by the Research Ethics Commission of Jinyintan Hospital (KY-2020-01.01). Informed consent was waived by the Research Ethics Commission.
46. Gu A, Farzadeh SN, Chang YJ, Kwong A, Lam S. Patterns of antihypertensive drug utilization among US adults with diabetes and comorbid hypertension: the national health and nutrition examination survey 1999–2014. Clin Med Insights Cardiol 2019; 13: 1179546819839418
47. Joint Committee for Guideline Revision. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension—A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol 2019; 16(3): 182–241
48. Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, Yang R, Di W, Wang Z, Li Z, Gao H, Liu L, Zhang G. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 2020; 9(1): 757–760
49. Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, He MA, Cheng LX, Huang K, Zeng QT. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Chin J Cardiol (Zhonghua Xin Xue Guan Bing Za Zhi) 2020; 48(0): E004
50. Bavishi C, Maddox TM, Messerli FH. Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers. JAMA Cardiol 2020; [Epub ahead of print] doi: 10.1001/jamacardio.2020.1282